Diabetes Drug Significantly Rduced Blood Sugar Levels Awaiting for U.S. Approval

A diabetes drug (from Novartis AG) currently awaiting U.S. approval significantly reduced blood sugar levels in patients with type 2 diabetes when given in combination with an older medicine called pioglitazone, researchers said on Tuesday.

The effects of the combination of 100 milligrams of Novartis’ Galvus (vildagliptin) and 30 mg of pioglitazone were even more dramatic in a subgroup of patients who had the highest blood sugar levels, according to data presented at the American Diabetes Association scientific meeting in Washington.

Patients treated with the combination had no significant weight gain and less fluid retention than those taking pioglitazone alone, researchers said.

Galvus belongs to a new class of diabetes medicines called DPP-4 inhibitors that are designed to enhance the body’s own ability to lower elevated blood sugar.

Filed under Blood Sugar Testing, Diabetes, Obesity | Comment Below


Leave a Reply

Protected by Comment Guard Pro